← Compound index
COMPOUND RECORD / VENTVIL

VentvilВентвил

A peptide mixture extracted from animal liver, studied in liver surgery research and a registered Phase II trial.

Source linked

What the studies found

Lab research · 2023

Combined effect of polypeptide complexes on organotypic rat tissue cultures

Findings for this preparation

Liver explant area index · Ventvil
+21 ± 5% (n=17 explants)Versus medium alone. Ventvil in spleen gave −2 ± 1% (n=18, p > 0.05).p < 0.05 versus medium for liver in the results text.
Liver explant area index · Ventvil + Thymalin
+20 ± 3% (n=21 explants)Versus medium alone. Thymalin alone gave +6 ± 2% (n=20, p > 0.05).p < 0.05 versus medium for the combination.
Spleen explant area index · Thymalin or Ventvil + Thymalin
+23 ± 3% (n=21) and +22 ± 3% (n=19)Explants compared with medium alone.Both p < 0.05.

At 20 ng/mL, Ventvil increased the liver explant area index by 21 ± 5%. The spleen-explant change was nonsignificant.

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences

Study notes · methods, sources and limitations

Participants or model Three-month-old Wistar rats supplied explants. Methods report 280 liver, 300 spleen and 250 kidney explants. Donor rat count is unspecified.

Design Rat tissue explants were cultured for three days. Polypeptide complexes were tested at 20 ng/mL. Plain culture medium was the control.

Important limitations

  • Explants are tissue fragments. Donor animal counts and handling of multiple explants from the same donor are unspecified. The article gives no direct statistical comparison of the combination against Ventvil alone. For Ventvil alone, the results text marks the liver result significant and the figure lacks a significance marker. The culture endpoint measures outgrowth.
  • These are tissue-culture results. The reported liver-area changes with Ventvil alone and with Thymalin were similar. The report gives no head-to-head significance test for those two conditions.

Molecular Medicine. 2023;21(1):61–64. · Original journal article

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Animal research · 2012

Injected Ventvil after partial liver removal in rats

Liver-cell mitotic index · 32 h
2.316 with Ventvil vs 1.364 with saline after surgeryThe narrative reports p < 0.05 versus saline. The table marks significance against the preoperative measure only.
Liver-cell mitotic index · 96 h
4.850 with Ventvil vs 2.012 with saline after surgeryAbout 2.4-fold in the reported groups. The patent prints a stricter p-value for the same means.The journal table marks p < 0.05 versus saline.
Cells in S phase · 96 h
No significant difference versus salineThe table shows 4.667 with Ventvil and 3.417 with saline.

At 96 hours the table lists a liver-cell mitotic index of 4.850 for treatment versus 2.012 for saline after surgery. The same values appear in an earlier patent that attributes them to injected synthetic EDL and reports a different animal count and dose.

More reported outcomes
Total dividing cells · 96 h
9.513 with Ventvil vs 5.429 with saline after surgeryThe authors report a 75% difference.The table marks p < 0.05 versus saline.
Study notes · methods, sources and limitations

Participants or model 28 male rats assigned to four groups. Total enrollment is given without arm or time-point counts.

Design Random allocation to intact saline, surgery with saline, or surgery with one of two subcutaneous Ventvil doses. The published outcome table gives one set of Ventvil figures.

Important limitations

  • The methods describe four groups. The table gives a single set of Ventvil figures, without showing dose-specific estimates or arm sizes. The entire numeric table repeats in patent RU2297239C1, Example 3. The journal describes 28 rats and calf-liver extract. The patent describes 18 rats and synthetic EDL. The sources leave the origin and attribution of the table unresolved. This was an animal surgery model. The paper measured cell division rather than functional recovery or clinical outcomes in people.
  • The 2012 journal and 2007 EDL patent give identical means and uncertainty values across the table but describe different preparations and animal counts. The data cannot establish a preparation-specific effect or serve as independent replication.

Belgorod State University Scientific Bulletin, Medicine and Pharmacy. 2012;10(129), issue 18/1:37–40. · Original journal article

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Lab research · 2015

[POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS].

Findings for this preparation

Ventvil was among the calf-tissue preparations tested in corresponding rat organotypic cultures. The abstract reports tissue-growth and marker changes across the preparations; it does not provide a separate numerical effect estimate for this preparation.

Study notes · methods, sources and limitations

Participants or model Organotypic tissue cultures from young and old rats

Important limitations

  • Tissue-culture growth is not organ regeneration in patients; equivalence to current branded products is unverified. Full methods, reporting completeness and independent replication remain to be appraised.

Advances in gerontology = Uspekhi gerontologii · PMID 26390619 · Original journal report

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Ventvil

Names in this research collection

Liver polypeptide complex

Research background

A liver-derived polypeptide complex discussed alongside Livagen (KEDA) in experimental hepatology. The extract and tetrapeptide are separate preparations.

Phase II sponsor and trial investigators ↗

Compound class
Tissue-derived polypeptide complex
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Phase I and Phase II placebo-controlled studies were registered. Results are unavailable in the linked records.

Study methods

Escalating-dose safety protocol, randomized liver disease protocol, a controlled rat surgery experiment and tissue-culture studies.

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

Trial registrations and original experimental publications.

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The available experimental studies leave human benefit and safety uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
PEPTIDE RESEARCH / OCT 2026

Related preparations and evidence

Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.

Liver: the molecular link

Ventvil → Livagen / KEDA

The 2020 Russian review discusses the liver complex and defined tetrapeptide together as separate experimental interventions.

Clinical evidence and limitations

The recovered review describes animal and cell models of fibrosis/hepatitis, not a human treatment trial.

Original model-specific papers and molecular characterization remain necessary. A shared research program is not proof of identical composition or effects.

Related preparations

Some references concern related extracts, reviews or molecular identification rather than direct studies of this compound.

Explore the full bioregulator collection ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2012

Injected Ventvil after partial liver removal in rats

At 96 hours the table lists a liver-cell mitotic index of 4.850 for treatment versus 2.012 for saline after surgery. The same values appear in an earlier patent that attributes them to injected synthetic EDL and reports a different animal count and dose.

Liver-cell mitotic index · 32 h · 2.316 with Ventvil vs 1.364 with saline after surgery · The narrative reports p < 0.05 versus saline. The table marks significance against the preoperative measure only.

Study notes and original source
2012Animal / experimentalFull text available

Injected Ventvil after partial liver removal in rats

Experimental calf-liver extract, peptide fractions up to 5 kDa, injected subcutaneously. · Original journal article

A. P. Ryzhak, B. I. Kuznik, G. A. Ryzhak · Belgorod State University Scientific Bulletin, Medicine and Pharmacy. 2012;10(129), issue 18/1:37–40.

At 96 hours the table lists a liver-cell mitotic index of 4.850 for treatment versus 2.012 for saline after surgery. The same values appear in an earlier patent that attributes them to injected synthetic EDL and reports a different animal count and dose.

Results and tables

Reported findings and study design

Random allocation to intact saline, surgery with saline, or surgery with one of two subcutaneous Ventvil doses. The published outcome table gives one set of Ventvil figures.

Population or model 28 male rats assigned to four groups. Total enrollment is given without arm or time-point counts.

Dose, route and schedule

Rats underwent removal of two-thirds of the liver and received saline or 0.01 or 0.1 mg Ventvil per rat subcutaneously at 2 and 24 hours after surgery. An intact group received saline. Liver histology was evaluated at 32 and 96 hours.

Protocol source ↗ · Russian journal PDF, pp. 37–40, methods and outcome table

Results · Russian journal PDF, pp. 37–40, methods and outcome table
MeasureResultComparison, timing and statistics
Liver-cell mitotic index · 32 h2.316 with Ventvil vs 1.364 with saline after surgeryThe narrative reports p < 0.05 versus saline. The table marks significance against the preoperative measure only.
Liver-cell mitotic index · 96 h4.850 with Ventvil vs 2.012 with saline after surgeryAbout 2.4-fold in the reported groups. The patent prints a stricter p-value for the same means. · The journal table marks p < 0.05 versus saline.
Cells in S phase · 96 hNo significant difference versus salineThe table shows 4.667 with Ventvil and 3.417 with saline.
Total dividing cells · 96 h9.513 with Ventvil vs 5.429 with saline after surgeryThe authors report a 75% difference. · The table marks p < 0.05 versus saline.

The 2012 journal and 2007 EDL patent give identical means and uncertainty values across the table but describe different preparations and animal counts. The data cannot establish a preparation-specific effect or serve as independent replication.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
28 male rats assigned to four groups. Total enrollment is given without arm or time-point counts.
Source reviewed
Russian journal PDF, pp. 37–40, methods and outcome table
Study limitations
  • The methods describe four groups. The table gives a single set of Ventvil figures, without showing dose-specific estimates or arm sizes.
  • The entire numeric table repeats in patent RU2297239C1, Example 3. The journal describes 28 rats and calf-liver extract. The patent describes 18 rats and synthetic EDL. The sources leave the origin and attribution of the table unresolved.
  • This was an animal surgery model. The paper measured cell division rather than functional recovery or clinical outcomes in people.

Reviewed 2026-11-14.

Read the source ↗

Planned study · 2017

Ventvil Phase I injection safety trial registration (HEP-VTL-01)

The Phase I registration lists 52 healthy volunteers and describes a double-blind placebo-controlled study of injection safety and tolerability. Clinical results remain unavailable.

Study notes and original source
2017Trial protocol / registrationFull text available

Ventvil Phase I injection safety trial registration (HEP-VTL-01)

Investigational intramuscular Ventvil liver polypeptide complex. · Clinical trial registration

SIA Peptides (sponsor) · Russian clinical-trial register mirror. Authorization No. 581, 3 November 2017

The Phase I registration lists 52 healthy volunteers and describes a double-blind placebo-controlled study of injection safety and tolerability. Clinical results remain unavailable.

Population / setting
52 healthy volunteers listed in the registration. An analyzed sample and arm sizes are unavailable.
Source reviewed
Registry entry and contemporary sponsor announcement
Study limitations
  • The public record lists the study as completed and supplies no group-level safety results or verified analyzed denominator.

Reviewed 2026-11-13.

Read the source ↗

Planned study · 2019

Ventvil Phase II placebo-controlled liver disease trial registration (VNT-08-2018)

The Phase II registry lists 130 planned participants in a randomized placebo-controlled comparison of injected Ventvil in alcohol-associated liver disease. Clinical results remain unavailable.

Study notes and original source
2019Trial protocol / registrationFull text available

Ventvil Phase II placebo-controlled liver disease trial registration (VNT-08-2018)

Ventvil 5 mg lyophilizate for intramuscular injection, manufactured by Samson-Med. · Clinical trial registration

MedInvest (sponsor) · Russian clinical-trial register entry via ClinLine. Authorization No. 120, 13 March 2019

The Phase II registry lists 130 planned participants in a randomized placebo-controlled comparison of injected Ventvil in alcohol-associated liver disease. Clinical results remain unavailable.

Population / setting
130 planned participants with alcohol-associated liver disease. Final enrollment and arm sizes are unavailable.
Source reviewed
Authorization No. 120, sponsor and contract research organization listings, investigator profiles and accessible Russian conference programs. Public sources provide registration details.
Study limitations
  • The registry mirror lists the trial as completed in 2020. The registry mirror enumerates 11 organizations. ClinLine gives 12 in its header and lists 11 by name. Both give 130 planned participants. Enrollment, arm doses and schedules, clinical outcomes and adverse-event counts remain unavailable.
  • 5 mg is the strength of the injectable vial. The registry record does not establish what each arm received.

Reviewed 2026-11-14.

Read the source ↗

Lab research · 2023

Combined effect of polypeptide complexes on organotypic rat tissue cultures

At 20 ng/mL, Ventvil increased the liver explant area index by 21 ± 5%. The spleen-explant change was nonsignificant.

Study notes and original source
2023In vitroFull text available

Combined effect of polypeptide complexes on organotypic rat tissue cultures

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences

Organ-derived polypeptide preparations applied directly to rat tissue in culture. · Original journal article

N. I. Chalisova, G. A. Ryzhak, E. S. Egozova · Molecular Medicine. 2023;21(1):61–64.

At 20 ng/mL, Ventvil increased the liver explant area index by 21 ± 5% versus medium alone (17 explants). Ventvil plus Thymalin gave a 20 ± 3% increase (21 explants). Ventvil alone had no significant effect in spleen explants.

Results and tables

Reported findings and study design

Rat tissue explants were cultured for three days. Polypeptide complexes were tested at 20 ng/mL. Plain culture medium was the control.

Population or model Three-month-old Wistar rats supplied explants. Methods report 280 liver, 300 spleen and 250 kidney explants. Donor rat count is unspecified.

Dose, route and schedule

Rat tissue fragments were incubated for three days at 37 °C in 3 mL of medium, with test extracts at a reported concentration of 20 ng/mL or medium alone. The area index compares total explant area with the central tissue area.

Protocol source ↗ · Russian full article, pp. 61–64, methods and results. Sample sizes refer to tissue explants.

Results · Russian full article, pp. 61–64, methods and results. Sample sizes refer to tissue explants.
MeasureResultComparison, timing and statistics
Liver explant area index · Ventvil+21 ± 5% (n=17 explants)Versus medium alone. Ventvil in spleen gave −2 ± 1% (n=18, p > 0.05). · p < 0.05 versus medium for liver in the results text.
Liver explant area index · Ventvil + Thymalin+20 ± 3% (n=21 explants)Versus medium alone. Thymalin alone gave +6 ± 2% (n=20, p > 0.05). · p < 0.05 versus medium for the combination.
Spleen explant area index · Thymalin or Ventvil + Thymalin+23 ± 3% (n=21) and +22 ± 3% (n=19)Explants compared with medium alone. · Both p < 0.05.
Kidney explant area index · Nephropept or Nephropept + Thymalin+27 ± 5% (n=22) and +20 ± 1% (n=17)Explants compared with medium alone. Nephropept in spleen gave −12 ± 1% (n=19, p > 0.05). · Both kidney results p < 0.05 versus medium.
Brain cortex explant area index · Cortexin + Thymalin+25 ± 1% (n=21 explants)Versus medium alone. The paper gives no Cortexin-only value in this comparison. · p < 0.05.
Spleen explant area index · Thymalin combinations+23 ± 1% with Nephropept (n=19), +24 ± 3% with Cortexin (n=20)Explants compared with medium alone. · Both p < 0.05.

These are tissue-culture results. The reported liver-area changes with Ventvil alone and with Thymalin were similar. The report gives no head-to-head significance test for those two conditions.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
Three-month-old Wistar rats supplied explants. Methods report 280 liver, 300 spleen and 250 kidney explants. Donor rat count is unspecified.
Source reviewed
Russian full article, pp. 61–64, methods and results. Sample sizes refer to tissue explants.
Study limitations
  • Explants are tissue fragments. Donor animal counts and handling of multiple explants from the same donor are unspecified.
  • The article gives no direct statistical comparison of the combination against Ventvil alone. For Ventvil alone, the results text marks the liver result significant and the figure lacks a significance marker. The culture endpoint measures outgrowth.

Reviewed 2026-11-14.

Read the source ↗

Lab research · 2015

[POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS].

Ventvil was among the calf-tissue preparations tested in corresponding rat organotypic cultures. The abstract reports tissue-growth and marker changes across the preparations; it does not provide a separate numerical effect estimate for this preparation.

Study notes and original source
2015In vitroEnglish abstract

[POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS].

· Original journal report

Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN · Advances in gerontology = Uspekhi gerontologii · PMID 26390619

Calf-tissue preparations, including Ventvil, stimulated corresponding tissue-culture growth with changes in proliferation-related markers.

Population / setting
Organotypic tissue cultures from young and old rats
Source reviewed
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
  • Tissue-culture growth is not organ regeneration in patients; equivalence to current branded products is unverified.
  • Full methods, reporting completeness and independent replication remain to be appraised.

Reviewed 2026-10-05.

Read the source ↗

Review of earlier studies · 2020

The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology

Reviews liver polypeptide complex Ventvil and KEDA/Livagen in experimental fibrosis and hepatitis, with immune and antioxidant outcomes.

Study notes and original source
2020ReviewEnglish abstract

The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK · Adv Gerontol 33(1):159-164. PMID 32362099

Reviews liver polypeptide complex Ventvil and KEDA/Livagen in experimental fibrosis and hepatitis, with immune and antioxidant outcomes.

Population / setting
Animal and in-vitro liver pathology models
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • Extract and tetrapeptide are separate interventions.
  • This is a review of experimental models, not a clinical hepatitis treatment trial.

Reviewed 2026-09-29.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗